| 2025 | 2024 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | -230,4 € | -10.9% | -207,7 € | +70.7% | -709,8 € | -484.6% | 184,5 € | -99.8% | 75,9 k € | +259.1% | 21,1 k € | +222.2% | -17,3 k € | -136.9% | -7,3 k € | -106.1% | 119,7 k € | -56.8% | 277,1 k € | +75.1% | 158,2 k € | +4348.3% | -3,7 k € | -8806.8% | -41,8 € | +96.2% | -1,1 k € | +29.2% | -1,6 k € | +38.1% | -2,5 k € | +20.4% | -3,2 k € | -33.1% | -2,4 k € | +51.9% | -5,0 k € | |
| EBITDA | -350,4 € | +54.5% | -770,0 € | +33.6% | -1,2 k € | +51.4% | -2,4 k € | -103.2% | 74,7 k € | +272.6% | 20,1 k € | +200.6% | -19,9 k € | -161.0% | -7,6 k € | -106.4% | 119,2 k € | -55.9% | 270,7 k € | +75.5% | 154,2 k € | +1939.0% | -8,4 k € | -2473.1% | -326,0 € | +76.5% | -1,4 k € | +24.8% | -1,8 k € | +46.0% | -3,4 k € | +9.8% | -3,8 k € | -25.7% | -3,0 k € | +60.7% | -7,7 k € | |
| Operating profit | -350,4 € | +54.5% | -770,0 € | +33.6% | -1,2 k € | +51.4% | -2,4 k € | -103.2% | 74,7 k € | +272.6% | 20,1 k € | +200.6% | -19,9 k € | -161.0% | -7,6 k € | -106.4% | 119,2 k € | -55.9% | 270,7 k € | +75.5% | 154,2 k € | +1939.0% | -8,4 k € | -2473.1% | -326,0 € | +76.5% | -1,4 k € | +24.8% | -1,8 k € | +46.0% | -3,4 k € | +9.8% | -3,8 k € | -25.7% | -3,0 k € | +60.7% | -7,7 k € | |
| Profit/loss | -11,5 k € | -28.3% | -9,0 k € | -354.3% | 3,5 k € | +107.8% | 1,7 k € | -97.6% | 71,8 k € | +274.9% | 19,1 k € | +181.4% | -23,5 k € | -199.3% | -7,9 k € | -106.8% | 114,9 k € | -53.6% | 247,4 k € | +89.0% | 130,9 k € | +126.5% | -493,1 k € | -122228.8% | -403,1 € | +73.1% | -1,5 k € | -162.6% | 2,4 k € | +166.0% | -3,6 k € | +6.8% | -3,9 k € | -24.0% | -3,1 k € | +59.7% | -7,8 k € | |
| Equity | -288,6 k € | -4.2% | -277,1 k € | -248.1% | 187,2 k € | +1.9% | 183,6 k € | +0.9% | 181,9 k € | +65.2% | 110,2 k € | +21.0% | 91,0 k € | -20.5% | 114,5 k € | -6.4% | 122,4 k € | +4.2% | 117,5 k € | +6.7% | 110,1 k € | +630.4% | -20,8 k € | -104.4% | 472,3 k € | -0.1% | 472,7 k € | -0.3% | 474,2 k € | +0.5% | 471,8 k € | -0.8% | 475,5 k € | -0.8% | 479,3 k € | -0.6% | 482,5 k € | |
| Total assets | 19,7 k € | +2.7% | 19,2 k € | -90.5% | 200,8 k € | +1.5% | 197,9 k € | +2.5% | 193,1 k € | -72.7% | 708,6 k € | +125.8% | 313,8 k € | -4.8% | 329,5 k € | +0.3% | 328,6 k € | -43.0% | 576,0 k € | +7.5% | 536,0 k € | -20.1% | 670,6 k € | +39.0% | 482,4 k € | +0.0% | 482,4 k € | -0.1% | 482,6 k € | +0.0% | 482,6 k € | +0.0% | 482,4 k € | -0.1% | 483,0 k € | -1.0% | 488,1 k € | |
| Cash | 30,7 € | +779.7% | 3,5 € | -95.4% | 75,9 € | -86.7% | 571,6 € | +12.9% | 506,4 € | -68.4% | 1,6 k € | +610.5% | 225,5 € | -44.6% | 407,0 € | +60.7% | 253,2 € | -95.8% | 6,0 k € | -12.1% | 6,8 k € | -63.8% | 18,8 k € | +48069.1% | 39,1 € | +178.6% | 14,0 € | -94.7% | 265,9 € | +30.3% | 204,1 € | — | 274,9 € | -94.3% | 4,8 k € | |||
| Debts | 308,3 k € | +4.1% | 296,3 k € | +2070.8% | 13,6 k € | -4.1% | 14,2 k € | +27.7% | 11,2 k € | -98.1% | 598,4 k € | +168.6% | 222,8 k € | +3.6% | 215,0 k € | +4.3% | 206,2 k € | -55.0% | 458,5 k € | +7.7% | 425,9 k € | -38.4% | 691,3 k € | +6767.0% | 10,1 k € | +4.4% | 9,6 k € | +14.8% | 8,4 k € | -21.7% | 10,7 k € | +55.4% | 6,9 k € | +86.3% | 3,7 k € | -34.6% | 5,7 k € | |
Public limited company · Hoogstraten · incorporated on 01/04/1999
Public limited company loss-making in the latest fiscal year. Cash position rising (+779.7%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
PR PHARMACEUTICALS is a Public limited company incorporated in 1999. Its main activity is: Management consultancy activities. Its registered office is in Hoogstraten.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette